Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 64

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 64
---
 officers, including Erez Aminov, the Chief Executive Officer of TELO. These arrangements may be tied to the successful completion and overall value of the Merger. This would be separate from the shares of
TELI Common Stock and Warrants issued to Mr. Aminov in connection with the Merger.

Structure

Under the Merger Agreement, Merger Sub, a wholly owned subsidiary of TELO formed in connection with the Merger, will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of TELO. Following the Merger, TELO expects to continue to trade on The Nasdaq Capital Market under the symbol “TELO.”

Executive Officers of the Combined Company Following the Merger

Immediately following the Merger, the executive management team of the combined company is expected to remain the same as prior to the Merger, and be comprised of the following individuals with such additional officers as may be added by the combined company:

| Name         |     | Position          
 with TELI         |
| Erez         
 Aminov       |     | Chief             
 Executive Officer |
| Alan         
 Weichselbaum |     | Chief             
 Financial Officer |

| 35 |

Directors of the Combined Company Following the Merger

Following the Merger, the combined company is expected to retain four of the current directors of TELO as were in office prior to the Merger, comprised of Matthew Pratt Whalen, CPA; Erez Aminov; Edward MacPherson, and Dr. Matthew Paul Del Giudice, with each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal. The aforementioned board of directors will maintain its audit committee, compensation committee and nominating and corporate governance committee, in accordance with the Nasdaq rules.

Merger Consideration and Exchange Ratio

For a discussion of the merger consideration and the Exchange Ratio, please see the section titled “ The Merger Agreement—Merger Consideration and Exchange Ratio.”

Accounting Treatment of Merger

TELI will account for the transaction as an asset purchase under the guidance provided in ASC 805-10-55-5 through ASC 805-10-55-9. TELI concluded that under the applicable rules, the Merger meets the criteria for an asset acquisition rather than a business combination. Neither TELO nor TELI has obtained a legal or tax opinion confirming that the Merger qualifies as a reorganization under Section 368(a) of the Code.

Material U